BMS forms immuno-oncology collaboration with 10 US and EU cancer institutes
This article was originally published in Scrip
Bristol-Myers Squibb (BMS) formed the International Immuno-Oncology Network (II-ON) with 10 research centers in the US and EU as a global collaboration between industry and academia to broaden global scientific understanding of how the body's immune system can be harnessed to fight cancer.
You may also be interested in...
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.